Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SetPoint System in moderate to severe rheumatoid arthritis
NCT04539964Phase 3Active, not recruiting
- Sponsor
- SetPoint Medical
- Start
- Jan 2021
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) (2 arms), sponsored by SetPoint Medical. Primary endpoint: American College of Rheumatology 20 Response at 48 weeks. Started Jan 2021; status: active, not recruiting.
02
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04539964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539964.